Device Recall Ventricular Assist Device 의 리콜

U.S. Food and Drug Administration에 따르면, 해당 리콜 는 United States 에서 HeartWare Inc 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

의료기기에 문제가 생겼을 경우 제조사가 이를 바로잡거나 시장에서 회수하는 조치를 말한다. 회수(Recall)는 의료기기에 결함이 있거나, 건강에 위협이 되거나, 또는 결함도 있고 건강에도 위협이 될 경우에 발생한다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Recall
  • 사례 ID
    73636
  • 사례 위험등급
    Class 1
  • 사례 연번
    Z-1887-2016
  • 사례 시작날짜
    2016-01-07
  • 사례 상황
    Open, Classified
  • 사례 국가
  • 사례 출처
    USFDA
  • 사례 출처 URL
  • 비고 / 경고
    U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
    The Parent Company was added by ICIJ.
    The parent company information is based on 2017 public records.
  • 데이터 추가 비고
    Ventricular (assisst) bypass - Product Code DSQ
  • 원인
    Heartware ventricular assist system battery cell experiencing premature depletion.
  • 조치
    The firm, HeartWare, sent an "URGENT MEDICAL DEVICE RECALL" letter dated January 7, 2016, to all their consignees informing them that of the HeartWare¿ HVAD Battery recall (device exchange). The letter described the product, problem and actions to be taken. The customers were instructed to: 1. Promptly complete the attached Acknowledgment Form and return it to HeartWare no later than 30 days from the date of this letter via email to HeartWare7786@stericycle.com or provide verbal Acknowledgement by calling Customer Service line , 1(844)491-7871; or fax to +1 (844)721-3044.. 2. Immediately identify and quarantine affected batteries in hospital inventory, and apply a RECALLED PRODUCT  DO NOT USE sticker (provided with this notice) as illustrated below. Replace quarantined inventory AC Adapters and batteries by requesting a Return Goods Authorization (RGA) through a qualified representative or directly through HeartWare Customer Service (via telephone 1-877-367-4823 or email cs@heartware.com). A qualified representative will update the Controller software for affected Controller units in inventory. 3. Identify, collect and quarantine affected product in patient possession. Arrange for current patients to bring their Batteries to a clinic appointment as soon as possible, (at least within the next three months), with urgency dependent upon individual patient circumstances. During their regularly scheduled appointment, a qualified representative will assist with quarantining and replacing affected product. Apply a RECALLED PRODUCT  DO NOT USE sticker as illustrated on affected batteries. Replace affected patient product using hospital inventory, and replace consumed hospital inventory by requesting an RGA as described above. 4. Return affected product to HeartWare. Your HeartWare representative will assist you with returning affected product to HeartWare. 5. Complete and return the attached Completion Form no later than 6 months from the date of this let

Device

  • 모델명 / 제조번호(시리얼번호)
    Serial numbers ranging BAT000001 to BAT199999.
  • 의료기기 분류등급
  • 의료기기 등급
    3
  • 이식된 장치?
    Yes
  • 유통
    US Nationwide distribution in the states of AL, AZ, CA, CO, CT, DE, FL, GA, IA, IL, IN, KY, LA, MA, MD, MI, MO, MS, NC, NE, NJ, NY, OH, OK, OR, PA, SC, TN, TX, UT, VA, WA, WI, and Washington D.C.
  • 제품 설명
    HeartWare Ventricular Assist System: HeartWare Battery, Lithium Ion, 14.8 V, Rx only. Catalog 1650 (US) and 1650, 1650-DE and A00035 (OUS) || Product Usage: || Used as a bridge-to-cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure. The HeartWare Ventricular Assist System is designed for in-hospital and out-of-hospital settings, including transportation via fixed-wing aircraft or helicopter.
  • Manufacturer

Manufacturer

  • 제조사 주소
    HeartWare Inc, 14400 NW 60th Ave, Miami Lakes FL 33014-2807
  • 제조사 모회사 (2017)
  • 제조사 의견
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    USFDA